September 18, 2025. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family. The company is developing therapies that target the root causes of cancer, aging, and age-related diseases.
Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors and activate inflammatory programs. Blocking these enzymes has long been viewed as scientifically important but clinically challenging, with KDM5 often described as challenging for development.
Telomir-1 has demonstrated the potential to reset both layers of control. The new in vitro studies showed Telomir-1 potently inhibited three members of the KDM5 family, blocking the silencing of protective genes and preventing the activation of harmful inflammatory pathways. Telomir-1 previously demonstrated activity across other families of histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A).
In other previously reported in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressors such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.
“This is a breakthrough,” said Erez Aminov, Chief Executive Officer of Telomir. “Showing that Telomir-1 can potently inhibit several family members of three types of histone demethylases, known to present drug discovery challenges such as selective targeting, cellular permeability, and context-dependent effects, is highly significant,” added Dr. Itzchak Angel, Chief Scientific Advisor at Telomir.
Telomir continues to advance IND-enabling studies and GMP scale-up for Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging. The Company expects these findings to support its upcoming IND submission.
Contact Information:
Helga Moya
info@telomirpharma.com
(786) 396-6723
Source: Telomir Pharmaceuticals, Inc
